Login
Linkedin
Twitter
Envelope
About EUnetHTA
History of EUnetHTA
JA 3 (2016-2020)
JA 2 Archive (2012-2015)
JA 1 Archive (2010-2012)
EUnetHTA Collaboration (2009)
EUnetHTA Project (2006-2008)
EUnetHTA Network
Organisation
The Executive Board
The Secretariat
Vision, Mission, and Values
EUnetHTA and the HTA Network
EUnetHTA Magazine
Winter 2020
Autumn 2019
Summer 2019
Winter 2018-2019
Autumn 2018
Summer 2018
Spring 2018
Winter 2017 – 2018
Autumn 2017
Acronyms
Covid-19 Response
Diagnostics
Treatments
Useful Links
Services
Assessment Submission
Early Dialogues
Early Dialogues for Pharmaceutical Products
Early Dialogues for Medical Devices
PLEG
Assessments
EUnetHTA Prioritisation List (EPL) – Pharmaceuticals
EUnetHTA Prioritisation List (EPL) – Other Technologies
Assessments REA (2016 – 2021)
Topic Identification, Selection and Prioritisation
National Uptake and Case Studies
PICO FAQ
Assessment Archive (2006 – 2015)
Assessment FAQ
Tools
HTA Core Model®
Methodology
REQueST® Tool
POP Database
EVIDENT Database
Declaration of Interest (DOI)
Submission Template for Pharma and Med. Devices
Companion Guide
Tools Archive
HTA Adaptation Toolkit
Get Involved
Patients
Industry
Health Care Professionals
Payers
Regulators
Events
2021 EUnetHTA Forum
2020 EUnetHTA Forum
2019 EUnetHTA Forum
2018 EUnetHTA Forum
2017 EUnetHTA Forum
Upcoming Events
Menu
About EUnetHTA
History of EUnetHTA
JA 3 (2016-2020)
JA 2 Archive (2012-2015)
JA 1 Archive (2010-2012)
EUnetHTA Collaboration (2009)
EUnetHTA Project (2006-2008)
EUnetHTA Network
Organisation
The Executive Board
The Secretariat
Vision, Mission, and Values
EUnetHTA and the HTA Network
EUnetHTA Magazine
Winter 2020
Autumn 2019
Summer 2019
Winter 2018-2019
Autumn 2018
Summer 2018
Spring 2018
Winter 2017 – 2018
Autumn 2017
Acronyms
Covid-19 Response
Diagnostics
Treatments
Useful Links
Services
Assessment Submission
Early Dialogues
Early Dialogues for Pharmaceutical Products
Early Dialogues for Medical Devices
PLEG
Assessments
EUnetHTA Prioritisation List (EPL) – Pharmaceuticals
EUnetHTA Prioritisation List (EPL) – Other Technologies
Assessments REA (2016 – 2021)
Topic Identification, Selection and Prioritisation
National Uptake and Case Studies
PICO FAQ
Assessment Archive (2006 – 2015)
Assessment FAQ
Tools
HTA Core Model®
Methodology
REQueST® Tool
POP Database
EVIDENT Database
Declaration of Interest (DOI)
Submission Template for Pharma and Med. Devices
Companion Guide
Tools Archive
HTA Adaptation Toolkit
Get Involved
Patients
Industry
Health Care Professionals
Payers
Regulators
Events
2021 EUnetHTA Forum
2020 EUnetHTA Forum
2019 EUnetHTA Forum
2018 EUnetHTA Forum
2017 EUnetHTA Forum
Upcoming Events
Results
News
Home
/
Outputs
/
EUnetHTA Joint Action 2 (2012-15)
/
Internal validity of randomised controlled trials
Internal validity of randomised controlled trials
January 20, 2016
16_WP7-SG3-GL-int_val_RCTs_amend2015
More news
This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our
Privacy Policy
and our
Terms of Use
.
Accept and Close
